2nd Quarter - Report

ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP

Firm
Client
Income
—
Expenses
$780,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trade Issues Supply chain & Buy American issues (COVID-19 related) Importation

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES —
HELEN DWIGHT —
THADDEUS FLOOD New —
CAROLINE QUAT NA
STEPHANIE WISWALL New —

Contacted: Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Value of Prescription Drugs Drug Pricing Transparency Personalized Medicine Diagnostics S. 1895, Lower Health Care Costs Act COVID-19 Vaccine and Therapy Development COVID-19 response packages Telehealth

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES —
HELEN DWIGHT —
THADDEUS FLOOD New —
CAROLINE QUAT NA
STEPHANIE WISWALL New —

Contacted: SENATE; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: S. 1895 (116th)

Medicare/Medicaid MMM

Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Changes to the Medicaid Drug Rebate Program (AMP Cap) Medicaid drug pricing reporting H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ESRD PPS, Medicare coverage ANPRM International Pricing Index Model for Medicare Part B Drugs Proposed Rule: Medicaid Program: Establishing Minimum Standards in Medicaid State Drug Utilization Value Based Arrangements

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES .
HELEN DWIGHT —
THADDEUS FLOOD New —
CAROLINE QUAT NA
STEPHANIE WISWALL New —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 107 (116th)

Pharmacy PHA

Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model Price Transparency Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program International Pricing Index Model (IPI) H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act S. 64, H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act NPRM: Importation of Prescription drugs

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES —
HELEN DWIGHT —
THADDEUS FLOOD New —
CAROLINE QUAT NA
STEPHANIE WISWALL New —

Contacted: Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: S. 64 (116th), H.R. 1499 (116th), S. 1416 (116th), H.R. 2375 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.